戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s of high-sensitivity C-reactive protein and asymmetric dimethylarginine).
2 en the SPIN1 triple Tudor domain and histone asymmetric dimethylarginine.
3                                              Asymmetric dimethylarginine (10 microM) or native low-de
4                                              Asymmetric dimethylarginine (ADMA) and homocysteine are
5 n (angiopoietin-2, osteoprotegerin, ICAM-1), asymmetric dimethylarginine (ADMA) and impaired microvas
6                                              Asymmetric dimethylarginine (ADMA) and monomethyl argini
7              The endogenous methylarginines, asymmetric dimethylarginine (ADMA) and N (G)-monomethyl-
8 uanidino-methylated arginines (MA) including asymmetric dimethylarginine (ADMA) and N(G)-methyl-l-arg
9 eased concentrations of two methylarginines, asymmetric dimethylarginine (ADMA) and N(G)-monomethyl-l
10               The endogenous methylarginines asymmetric dimethylarginine (ADMA) and N(G)-monomethyl-L
11                           The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylargin
12 anidinomethylated arginines (MAs), including asymmetric dimethylarginine (ADMA) and NG-methyl-L-argin
13 and positive associations were found for the asymmetric dimethylarginine (ADMA) and symmetric dimethl
14 r (15)N-arginine intravenous infusion and on asymmetric dimethylarginine (ADMA) and symmetric dimethy
15 n mammalian cells: monomethylarginine (MMA), asymmetric dimethylarginine (ADMA) and symmetric dimethy
16 ndogenous arginine derivatives homoarginine, asymmetric dimethylarginine (ADMA) and symmetric dimethy
17            Elevated plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with a
18                          Increased levels of asymmetric dimethylarginine (ADMA) are associated with e
19 oth fibroblast growth factor 23 (FGF-23) and asymmetric dimethylarginine (ADMA) are associated with p
20         The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) circulates in plasma,
21                           Elevated levels of asymmetric dimethylarginine (ADMA) correlate with risk f
22     We sought to determine if a reduction in asymmetric dimethylarginine (ADMA) enhances endothelial
23 ) bioavailability, inflammation profile, and asymmetric dimethylarginine (ADMA) in patients undergoin
24 ncentrations of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) in the hypoxia-induce
25           We have recently demonstrated that asymmetric dimethylarginine (ADMA) induces the transloca
26               We sought to determine whether asymmetric dimethylarginine (ADMA) inhibits nitric oxide
27                                              Asymmetric dimethylarginine (ADMA) is an endogenous comp
28                                              Asymmetric dimethylarginine (ADMA) is an endogenous inhi
29                                              Asymmetric dimethylarginine (ADMA) is an endogenous inhi
30                                              Asymmetric dimethylarginine (ADMA) is an endogenous meta
31 decreased, and the inhibitor of NO synthesis asymmetric dimethylarginine (ADMA) is increased.
32       The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been c
33                                              Asymmetric dimethylarginine (ADMA) plays a crucial role
34 rculating concentrations of the uremic toxin asymmetric dimethylarginine (ADMA) were elevated in 2KO
35 ne, and the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) were measured with li
36 ork implicating the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA), a cardiotoxic hormon
37           DDAH1 is a key catabolic enzyme of asymmetric dimethylarginine (ADMA), a major endogenous n
38                                              Asymmetric dimethylarginine (ADMA), an endogenous inhibi
39                                         Both asymmetric dimethylarginine (ADMA), an endogenous inhibi
40                                              Asymmetric dimethylarginine (ADMA), an endogenous inhibi
41             Elevated blood concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibi
42 rogens regulate the metabolism or release of asymmetric dimethylarginine (ADMA), an endogenous inhibi
43 ffects in part by elevating plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibi
44                          Increased levels of asymmetric dimethylarginine (ADMA), an endogenous nitric
45 dy prospectively determined plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric
46 l contributor to endothelial pathobiology is asymmetric dimethylarginine (ADMA), an endogenous nitric
47                                              Asymmetric dimethylarginine (ADMA), an endogenous nitric
48 l contributor to endothelial pathobiology is asymmetric dimethylarginine (ADMA), an endogenous NO syn
49 AT) and assessed associations with arginine, asymmetric dimethylarginine (ADMA), and hemolysis.
50 aw the next morning for soluble CD40 ligand, asymmetric dimethylarginine (ADMA), and nitrotyrosine le
51 1) strictly generates monomethylarginine and asymmetric dimethylarginine (ADMA), but not symmetric di
52  risk factors, total homocysteine (tHcy) and asymmetric dimethylarginine (ADMA), correlate with decre
53  Plasma was assayed for endothelin 1 (ET-1), asymmetric dimethylarginine (ADMA), intercellular adhesi
54 dogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), is elevated in patie
55 a levels of arginine, citrulline, ornithine, asymmetric dimethylarginine (ADMA), symmetric dimethylar
56 function and raised plasma concentrations of asymmetric dimethylarginine (ADMA), the endogenous inhib
57                                              Asymmetric dimethylarginine (ADMA), which inhibits NO sy
58  systemic levels of l-arginine and increased asymmetric dimethylarginine (ADMA).
59 nverts TbPRMT7 into a type I PRMT, producing asymmetric dimethylarginine (ADMA).
60 e endogenous nitric-oxide synthase inhibitor asymmetric dimethylarginine (ADMA).
61 genous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA).
62 onist of NO synthase has been characterized: asymmetric dimethylarginine (ADMA).
63 ular disease by metabolising the risk factor asymmetric dimethylarginine (ADMA).
64                                We focused on asymmetric dimethylarginine (ADMA, the endogenous inhibi
65             CS patients had higher levels of asymmetric dimethylarginine (ADMA; P<0.0001), symmetric
66                                              Asymmetric-dimethylarginine (ADMA) limits NO production
67 e endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine [ADMA, via inhibition of dim
68 bin [TAT] complex), endothelial dysfunction (asymmetric dimethylarginine [ADMA]), and platelet-derive
69                                              Asymmetric dimethylarginine also stimulated MCP-1 format
70 vels of apolipoprotein AI and high levels of asymmetric dimethylarginine, an endogenous inhibitor of
71 lammation (C-reactive protein), or levels of asymmetric dimethylarginine, an endogenous inhibitor of
72 aminohydrolases (DDAHs) are known to degrade asymmetric dimethylarginine, an endogenous inhibitor of
73 would be expected to lead to accumulation of asymmetric dimethylarginine and inhibition of NOS.
74 that 3.7% of the molecules naturally contain asymmetric dimethylarginine and/or monomethylarginine.
75  Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are
76 elin-1, advanced glycation end-products, and asymmetric dimethylarginine), can be involved.
77 1(-/-) mice showed a significant increase of asymmetric dimethylarginine concentration in plasma (1.4
78 ferase 1 (PRMT1) catalyzing the formation of asymmetric dimethylarginines has been implicated in canc
79                                              Asymmetric dimethylarginine increases endothelial oxidat
80                                              Asymmetric dimethylarginine-induced monocyte binding was
81                                              Asymmetric dimethylarginine is an endogenous inhibitor o
82                                              Asymmetric dimethylarginine is eliminated largely by the
83 atocrit levels were lower and plasma CFH and asymmetric dimethylarginine levels were higher in patien
84  vascular cell adhesion molecule (VCAM), and asymmetric dimethylarginine levels were measured.
85                     PRMT1, which deposits an asymmetric dimethylarginine mark on histone/non-histone
86                                              Asymmetric dimethylarginine may be an endogenous proathe
87                                              Asymmetric dimethylarginine plays a role in endothelial
88  receptor capable of selectively recognizing asymmetric dimethylarginine (Rme2a).
89 eduction in the level of p-cresol sulfate or asymmetric dimethylarginine to significant reductions in
90 ype II activity) as well as small amounts of asymmetric dimethylarginine (type I activity).
91 pending on the resulting methylated product: asymmetric dimethylarginine (Type I PRMT), symmetric dim
92 ients were characterized by higher levels of asymmetric dimethylarginine, tyramine, 2-hydroxybutyric
93  uremic milieu contains increased amounts of asymmetric dimethylarginine, we speculate that such accu
94  stable nitric oxide oxidation products, and asymmetric dimethylarginine were abnormal in patients wi
95 plasma levels of l-arginine, arginase-1, and asymmetric dimethylarginine were measured at serial time
96 vely small amounts of monomethylarginine and asymmetric dimethylarginine were produced.
97 h severe malaria, hematocrit and CFH but not asymmetric dimethylarginine were significant predictors.
98 il, betaine, symmetric dimethylarginine, and asymmetric-dimethylarginine), were also increased in uri